Ginkgetin |
Catalog No.GC31717
One-Click Copy Product Info
|
Ginkgetin is a natural biflavonoid compound extracted from Ginkgo biloba leaves, inhibits the Wnt signaling pathway (IC₅₀=5.92μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 481-46-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ginkgetin is a natural biflavonoid compound extracted from Ginkgo biloba leaves, inhibits the Wnt signaling pathway (IC₅₀=5.92μM)[1]. Ginkgetin exhibits multiple pharmacological activities, including anticancer, anti-inflammatory, antimicrobial, antioxidant, and neuroprotective effects[2]. Ginkgetin can be used to treat coronary heart disease, angina pectoris, and hypertension[3-4].
In vitro, co-treatment of A549, NCI-H460, and SPC-A-1 non-small cell lung cancer cells with Ginkgetin (5μM) and Cisplatin (5μM) for 48 hours significantly induces ferroptosis and enhances the cytotoxic effects of Cisplatin[5]. Treatment of ovarian cancer cells A2780, SK-OV-3, and CP70 with Ginkgetin (0.625–80μM) for 24 hours significantly inhibits cell proliferation, induces apoptosis, and reduces cell migration and invasion capabilities[6].
In vivo, intraperitoneal injection of Ginkgetin (5mg/kg) every other day for 2 months in a Doxorubicin (Dox; 10mg/kg)-induced aging C57BL/6J mouse model significantly alleviates aging-related pathological changes in multiple tissues (including kidney, liver, muscle, and spleen) and improves motor function[7]. Oral administration of Ginkgetin (25, 50, 100mg/kg) twice weekly for 8 weeks in ovariectomized (OVX) C57BL/6J mice significantly attenuates bone loss[8].
References:
[1] Ye ZN, Yu MY, Kong LM, et al. Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of Medulloblastoma. Nat Prod Bioprospect. 2015 Mar 29;5(2):91–7.
[2] Liu XG, Lu X, Gao W, et al. Structure, synthesis, biosynthesis, and activity of the characteristic compounds from Ginkgo biloba L. Nat Prod Rep. 2022 Mar 23;39(3):474-511.
[3] Xiong B, Lu JJ, Guo H, et al. Ginkgetin from Ginkgo biloba: mechanistic insights into anticancer efficacy. Nat Prod Bioprospect. 2025 Aug 5;15(1):50.
[4] Adnan M, Rasul A, Hussain G, et al. Ginkgetin: A natural biflavone with versatile pharmacological activities. Food Chem Toxicol. 2020 Nov;145:111642.
[5] Lou JS, Zhao LP, Huang ZH, et al. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 2021 Jan;80:153370.
[6] Liu Y, Ye J, Fan Z, et al. Ginkgetin Alleviates Inflammation and Senescence by Targeting STING. Adv Sci (Weinh). 2025 Jan;12(2):e2407222.
[7] Geng Z, Zuo L, Li J, et al. Ginkgetin improved experimental colitis by inhibiting intestinal epithelial cell apoptosis through EGFR/PI3K/AKT signaling. FASEB J. 2024 Jul 31;38(14):e23817.
[8] Wei G, Liang X, Wu F, et al. Ginkgetin attenuates bone loss in OVX mice by inhibiting the NF-κB/IκBα signaling pathway. PeerJ. 2024 Jul 10;12:e17722.
| Cell experiment [1]: | |
|
Cell lines |
A2780, SK-OV-3, and CP70 (human ovarian cancer cell lines); KGN (human ovarian granulosa cell-like) and H9c2 (rat cardiomyocytes) as normal controls |
|
Preparation Method |
OC cells and normal cells were cultured in high-glucose DMEM medium supplemented with 10% FBS at 37°C, 5% CO₂. Cells were treated with Ginkgetin at concentrations of 0.625–80μM for 24 hours. |
|
Reaction Conditions |
0.625–80μM; 24h |
|
Applications |
Ginkgetin dose-dependently inhibited proliferation, migration, and invasion of OC cells, and induced apoptosis via downregulation of Bcl-2 and upregulation of Bax/p53. Ginkgetin suppressed JAK2/STAT3 and MAPK signaling pathways and reduced SIRT1 protein expression. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6J female mice |
|
Preparation Method |
Mice underwent ovariectomy (OVX) to induce bone loss. Ginkgetin (25–100mg/kg) was orally administered twice weekly for 8 weeks. |
|
Dosage form |
25–100mg/kg; orally administered; for 8 weeks |
|
Applications |
In OVX mice, Ginkgetin attenuated bone loss by improving bone density (BMD, BV/TV) and trabecular structure, suppressing osteoclast formation via inhibition of NF-κB/IκBα signaling, and reducing osteoclast-related genes. |
|
References: |
|
| Cas No. | 481-46-9 | SDF | |
| Canonical SMILES | OC1=CC(O)=C2C(OC(C3=CC=C(O)C=C3)=CC2=O)=C1C4=CC(C(OC5=CC(OC)=CC(O)=C56)=CC6=O)=CC=C4OC | ||
| Formula | C32H22O10 | M.Wt | 566.51 |
| Solubility | DMSO : ≥ 83.3 mg/mL (147.04 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7652 mL | 8.826 mL | 17.6519 mL |
| 5 mM | 353 μL | 1.7652 mL | 3.5304 mL |
| 10 mM | 176.5 μL | 882.6 μL | 1.7652 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)